Chong Kun Dang Pharmaceutical Corp.
🇰🇷South Korea
- Country
- 🇰🇷South Korea
- Ownership
- Public
- Established
- 1941-01-01
- Employees
- 2.3K
- Market Cap
- -
- Website
- http://www.ckdpharm.com
Study to Investigate the Effects of Food on the Pharmacokinetics/Pharmacodynamics of CKD-519
Phase 1
Completed
- Conditions
- Healthy Volunteers
- Interventions
- Drug: CKD-519 100mgDrug: CKD-519 200mg
- First Posted Date
- 2016-09-09
- Last Posted Date
- 2017-02-23
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 48
- Registration Number
- NCT02894541
- Locations
- 🇰🇷
Korea university medical center, Seoul, Sungbuk-gu, Korea, Republic of
Evaluate the Drug-drugs Interaction Between Lobeglitazone and Empagliflozin
Phase 1
- Conditions
- Diabetes Mellitus, Type II
- Interventions
- First Posted Date
- 2016-08-03
- Last Posted Date
- 2016-08-09
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 30
- Registration Number
- NCT02854748
- Locations
- 🇰🇷
Dong A University Hospital, Seo-gu, Busan, Korea, Republic of
CKD-396 Drug-drug Interaction Study(B) (CKD-396 DDI(B) P1)
Phase 1
Completed
- Conditions
- Diabetes Mellitus Type 2
- Interventions
- First Posted Date
- 2016-07-11
- Last Posted Date
- 2017-08-09
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 20
- Registration Number
- NCT02827890
- Locations
- 🇰🇷
Chonbuk National University Hospital, Jeonju-si, Korea, Republic of
CKD-396 Drug-drug Interaction Study(A) (CKD-396 DDI(A) P1)
Phase 1
Completed
- Conditions
- Diabetes Mellitus, Type II
- Interventions
- Drug: Duvie Tab. 0.5mgDrug: Duvie Tab. 0.5mg + Januvia Tab. 100mg
- First Posted Date
- 2016-07-07
- Last Posted Date
- 2016-07-11
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 20
- Registration Number
- NCT02824874
- Locations
- 🇰🇷
Chonbuk National University Hospital, Jeonju-si, Korea, Republic of
Bioequivalence Study (Candesartan 16 mg and Amlodipine 5 mg) - B
Phase 1
Completed
- Conditions
- Hypertension
- Interventions
- Drug: CKD-330 16/5mg - B
- First Posted Date
- 2016-06-23
- Last Posted Date
- 2016-06-23
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 32
- Registration Number
- NCT02811731
Clinical Trial to Evaluate the Efficacy and Safety of CKD-390 Tablet
- First Posted Date
- 2016-06-20
- Last Posted Date
- 2016-06-21
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 158
- Registration Number
- NCT02805738
- Locations
- 🇰🇷
Korea University Ansan Hospital, Ansan, Gyeonggi-do, Korea, Republic of
🇰🇷Bundang Cha Medical Center, Bundang, Gyeonggi-do, Korea, Republic of
🇰🇷Jeju National University Hospital, Jeju, Korea, Republic of
Bioequivalence Study (Candesartan 16 mg and Amlodipine 5 mg) - A
Phase 1
Completed
- Conditions
- Hypertension
- Interventions
- Drug: CKD-330 16/5mg - A
- First Posted Date
- 2016-06-16
- Last Posted Date
- 2016-06-16
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 32
- Registration Number
- NCT02801526
Study to Evaluate the Efficacy and Safety of CKD-350
Phase 3
- Conditions
- Dry Eye Syndrome
- Interventions
- Drug: Isotonic 0.3% Sodium HyaluronateDrug: Xenobella
- First Posted Date
- 2016-05-19
- Last Posted Date
- 2016-05-19
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 138
- Registration Number
- NCT02777723
- Locations
- 🇰🇷
Gangnam Severance Hospital, Seoul, Korea, Republic of
🇰🇷The Catholic University of Korea Seoul ST. MARY'S Hospital, Seoul, Korea, Republic of
🇰🇷Samsung Medical Center, Seoul, Korea, Republic of
Study to Investigate the Safety/Tolerability and Pharmacokinetics/Pharmacodynamics of CKD-519
- First Posted Date
- 2016-04-28
- Last Posted Date
- 2017-07-13
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 24
- Registration Number
- NCT02753504
- Locations
- 🇰🇷
Severance Hospital, Seoul, Seodaemun-gu, Korea, Republic of
A Clinical Study to Compare the Pharmacokinetic Characteristics of CKD-395 0.25/500mg in Healthy Male Volunteers
Phase 1
Completed
- Conditions
- Diabetes Mellitus, Type II
- Interventions
- Drug: Duvie Tab. 0.5mg, Glucophage XR Tab. 500mgDrug: CKD-395 0.25/500mg
- First Posted Date
- 2016-02-19
- Last Posted Date
- 2017-08-09
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 26
- Registration Number
- NCT02685774
- Locations
- 🇰🇷
Chonbuk National University Hospital, Jeonju-si, Jeollabuk-do, Korea, Republic of
© Copyright 2025. All Rights Reserved by MedPath